[SCHEDULE 13G/A] Quantum Biopharma Ltd. Class B Subordinate Voting Shares SEC Filing

Rhea-AI Filing Summary

Malone Wealth Ventures LLC filed an Amendment No. 1 to Schedule 13G disclosing its ownership in Quantum Biopharma Ltd. (QNTM) common stock as of 11 June 2025.

• Aggregate beneficial ownership: 689,421 shares, representing 19.9 % of the outstanding class.
• Sole voting power: 109,765 shares (16 % of the firm’s economic stake), indicating limited influence on shareholder votes.
• Sole dispositive power: 689,421 shares; the firm can sell or otherwise dispose of the entire position without third-party consent.
• Shared voting/dispositive power: 0 shares.
• The shares are held in the ordinary course of business; Malone Wealth Ventures certifies it is not seeking to influence control of Quantum Biopharma.
• The filing is made under Rules 13d-1(b), 13d-1(c) and 13d-1(d), affirming the filer’s status as, among other categories, an investment adviser and parent holding company.
• Clients of Malone Wealth Ventures are the economic beneficiaries of the shares, but no individual client holds more than 5 % of the class.

This near-20 % stake makes Malone Wealth Ventures the largest known passive holder of QNTM, signalling meaningful external confidence while keeping governance influence muted due to the relatively low voting power disclosed.

Positive

• Significant institutional commitment: Malone Wealth Ventures’ 19.9 % stake introduces a well-capitalised, professional investor base.
• Passive intent certified: The filer states the shares were acquired in the ordinary course of business, reducing immediate control or activist risk.

Negative

• Limited voting alignment: Only 109,765 of the 689,421 shares carry sole voting power, creating a gap between economic and governance influence.

Insights

Securities Analyst

TL;DR – Malone Wealth Ventures now owns 19.9 % of QNTM, signalling strong institutional interest but limited voting control.

The filing reveals a sizable passive stake just below the 20 % threshold. Because the shares are held for investment purposes and not control, the development is generally supportive of QNTM’s equity story by introducing a committed, professionally managed holder. Economic exposure is substantial, yet the adviser retains voting rights over only 110 k shares, limiting its direct influence on corporate actions. The disclosure may enhance liquidity and market visibility, but it does not immediately affect operations or capital structure. Overall, the news is moderately positive and impactful given the stake size.

Corporate Governance Expert

TL;DR – Large economic stake with low voting power reduces takeover risk but raises alignment questions.

Malone Wealth Ventures controls nearly one-fifth of QNTM’s equity but commands voting authority over only 16 % of that stake. This structure suggests brokerage or custodial relationships where clients retain voting rights. For governance, the company enjoys capital support without conceding proportional influence, lowering the probability of activist campaigns by this holder. Conversely, divergence between economic and voting interests can dilute minority shareholders’ ability to co-alesce around stewardship initiatives. The filing is impactful because ownership concentration approaches regulatory and poison-pill trigger levels.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Quantum Biopharma Ltd.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

74764Y205

(CUSIP Number)

06/11/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 74764Y205

1

Names of Reporting Persons

Malone Wealth Ventures LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 109,765.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 689,421.00
8	Shared Dispositive Power

9

Aggregate Amount Beneficially Owned by Each Reporting Person

689,421.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

19.9 %

12

Type of Reporting Person (See Instructions)

IA

Comment for Type of Reporting Person: Les Gro

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Quantum Biopharma Ltd.
(b)	Address of issuer's principal executive offices: 55 UNIVERSITY AVENUE, SUITE 1003, 55 UNIVERSITY AVENUE, SUITE 1003, TORONTO, ONTARIO, CANADA, M5J 2H7.
Item 2.
(a)	Name of person filing: Malone Wealth Ventures LLC
(b)	Address or principal business office or, if none, residence: 9201 W State St. Ste 126 Boise, ID 83714
(c)	Citizenship: United States
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 74764Y205
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 689421
(b)	Percent of class: 19.9 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 109765
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 689421
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Clients of Malone Wealth Ventures LLC have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, the securities reported herein. No individual client is known to have such interest relating to more than five percent of the class.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Malone Wealth Ventures LLC

Signature:	Kevin M Malone
Name/Title:	President and CEO
Date:	06/30/2025

FAQ

How many Quantum Biopharma (QNTM) shares does Malone Wealth Ventures own?

The filing reports 689,421 common shares beneficially owned.

What percentage of QNTM’s outstanding shares does this represent?

Malone Wealth Ventures holds 19.9 % of the outstanding class.

Does Malone Wealth Ventures seek control of Quantum Biopharma?

No. The Schedule 13G certification states the shares were acquired solely for investment purposes, not to influence control.

How much voting power does Malone Wealth Ventures control in QNTM?

It has sole voting power over 109,765 shares and no shared voting power.

Who benefits economically from the disclosed shares?

Clients of Malone Wealth Ventures are the economic beneficiaries; no single client holds over 5 % of the class.